Table 2.
Percentage of Patients Achieving Target Dose of GDMT at Baseline, 90 Days, 6 Months, 12 Months, and 24 Months Stratified by Baseline AFa,b
| Variables | No AF (n=535), % | AF (n=358), % | P value |
|---|---|---|---|
| Baseline | |||
| ACE inhibitor | 39.8 (37.8) | 41.8 (40.9) | .57 |
| ARB | 40.7 (27.8) | 38.7 (30.4) | .69 |
| Beta blocker | 27.8 (22.9) | 42.5 (61.4) | <.001 |
| MRA | 48.8 (25.4) | 52.7 (27.9) | .14 |
| 90 days | |||
| ACE inhibitor | 49.9 (39.4) | 50.7 (42.5) | .86 |
| ARB | 42.5 (29.4) | 35.8 (32.8) | .55 |
| Beta blocker | 39.0 (35.4) | 45.1 (29.6) | .01 |
| MRA | 55.5 (23.6) | 55.1 (28.2) | .89 |
| 6 months | |||
| ACE inhibitor | 52.7 (39.2) | 49.8 (39.4) | .49 |
| ARB | 49.8 (60.1) | 41.9 (29.3) | .33 |
| Beta blocker | 43.5 (29.4) | 46.4 (29.7) | .23 |
| MRA | 55.7 (32.3) | 56.0 (31.5) | .93 |
| 12 months | |||
| ACE inhibitor | 57.9 (42.7) | 50.1 (45.1) | .18 |
| ARB | 50.7 (47.7) | 44.7 (30.9) | .44 |
| Beta blocker | 44.5 (30.4) | 47.2 (30.9) | .34 |
| MRA | 59.8 (35.4) | 55.2 (28.9) | .26 |
| 24 months | |||
| ACE inhibitor | 60.9 (46.3) | 53.4 (44.1) | .39 |
| ARB | 49.5 (38.6) | 42.9 (27.9) | .54 |
| Beta blocker | 51.3 (51.3) | 42.0 (28.4) | .09 |
| MRA | 55.7 (32.3) | 56.0 (31.5) | .36 |
a
ACE, angiotensin-converting enzyme; AF, atrial fibrillation; ARB, angiotensin receptor blocker; GDMT, guideline-directed medical therapy; MRA, mineralocorticoid receptor antagonist.
b
Values are reported as mean (standard deviation). Boldface P values represent statistical significance.